|
ERI2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.03403960341575E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.0831999996963E-07 |
| Normal-vs-Stage2 |
2.38929999999415E-05 |
| Normal-vs-Stage3 |
8.66406946187226E-12 |
| Normal-vs-Stage4 |
6.46200000176123E-08 |
| Stage1-vs-Stage2 |
5.972800E-01 |
| Stage1-vs-Stage3 |
1.215660E-02 |
| Stage1-vs-Stage4 |
7.438100E-02 |
| Stage2-vs-Stage3 |
2.978200E-02 |
| Stage2-vs-Stage4 |
6.286000E-02 |
| Stage3-vs-Stage4 |
8.396600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.08058006986766E-12 |
| Normal-vs-AfricanAmerican |
3.379200E-04 |
| Normal-vs-Asian |
1.77422999999566E-05 |
| Caucasian-vs-AfricanAmerican |
7.758600E-01 |
| Caucasian-vs-Asian |
4.250200E-01 |
| AfricanAmerican-vs-Asian |
7.954600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.44600004087425E-09 |
| Normal-vs-Female |
2.86748402800185E-12 |
| Male-vs-Female |
7.776000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.80959999990438E-07 |
| Normal-vs-Age(41-60Yrs) |
5.72963898548551E-12 |
| Normal-vs-Age(61-80Yrs) |
2.03629999528943E-08 |
| Normal-vs-Age(81-100Yrs) |
4.780300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.772100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.881200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.406200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.654400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.619000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.551600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.390340E-04 |
| Classical-VS-Follicular |
1.021820E-01 |
| Classical-VS-Other |
6.320600E-01 |
| Classical-VS-Normal |
4.84019999635876E-08 |
| Tall-VS-Follicular |
1.87189999999449E-05 |
| Tall-VS-Other |
1.342350E-02 |
| Tall-VS-Normal |
8.24729173842798E-12 |
| Follicular-VS-Other |
9.456800E-01 |
| Follicular-VS-Normal |
1.8236999999921E-05 |
| Other-VS-Normal |
5.273900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.04839520082601E-11 |
| Normal-vs-N1 |
3.91269999999722E-06 |
| N0-vs-N1 |
9.094400E-01 |
|
|
